Key clinical point: Patients with first-ever stroke and type 2 diabetes mellitus (T2D) who receive metformin treatment (MT) show lower stroke severity, case fatality, and disability rates.
Major finding: MT vs non-MT group had a lower rate of in-hospital case fatality (odds ratio [OR] 0.63; 95% CI 0.47-0.84) , 12-month case fatality (OR 0.69; 95% CI 0.50-0.88) , and 12-month disability (OR 0.83; 95% CI 0.70-0.95).
Study details: The data come from a prospective, hospital-based cohort study including 7587 patients with first-ever stroke and T2D, of which 3593 (47.36%) received MT (MT group) and 3994 (52.64%) did not receive MT (non-MT group).
Disclosures: This study was supported by the National Major Public Health Service Projects, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Natural Science Foundation of Tianjin, and China Postdoctoral Science Foundation, among others. The authors declared no conflicts of interest.
Source: Tu WJ et al. Metformin use is associated with low risk of case fatality and disability rates in first-ever stroke patients with type 2 diabetes. Ther Adv Chronic Dis. 2022 (Apr 19). Doi: 10.1177/20406223221076894